Synaptic protein CSF levels relate to memory scores in individuals without dementia

Synaptic protein CSF levels relate to memory scores in individuals without dementia

Background: We investigated how cerebrospinal fluid levels of synaptic proteins associate with memory function in normal cognition (CN) and mild cognitive impairment (MCI), and investigated the effect of amyloid positivity on these associations. Methods: We included 242 CN (105(43%) abnormal amyloid...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Wesenhagen, KEJ, de Leeuw, DM, Tomassen, J, Gobom, J, Bos, I, Vos, SJB, Martinez-Lage, P, Tainta, M, Popp, J, Peyratout, G, Tsolaki, M, Vandenberghe, R, Freund-Levi, Y, Verhey, F, Lovestone, S, Streffer, J, Dobricic, V, Blennow, K, Scheltens, P, Smit, AB, Bertram, L, Teunissen, CE, Zetterberg, H, Tijms, BM
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	BioMed Central 2025

Míreanna comhchosúla

Synaptic protein CSF levels relate to memory scores in individuals without dementia
de réir: Kirsten E. J. Wesenhagen, et al.
Foilsithe / Cruthaithe: (2025-03-01)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
de réir: Betty Marije Tijms, et al.
Foilsithe / Cruthaithe: (2021-08-01)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
de réir: Elles Konijnenberg, et al.
Foilsithe / Cruthaithe: (2020-05-01)

Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies
de réir: Delvenne, A, et al.
Foilsithe / Cruthaithe: (2024)

CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease
de réir: Delvenne, A, et al.
Foilsithe / Cruthaithe: (2024)

Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies
de réir: Aurore Delvenne, et al.
Foilsithe / Cruthaithe: (2024-07-01)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
de réir: Pieter Jelle Visser, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
de réir: Pieter Jelle Visser, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort
de réir: Westwood, S, et al.
Foilsithe / Cruthaithe: (2020)

Inflammatory biomarkers in Alzheimer's disease plasma
de réir: Morgan, A, et al.
Foilsithe / Cruthaithe: (2019)

MRI predictors of amyloid pathology: results from the EMIF-AD multimodal biomarker discovery study
de réir: ten Kate, M, et al.
Foilsithe / Cruthaithe: (2018)

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
de réir: Shi, L, et al.
Foilsithe / Cruthaithe: (2019)

Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset
de réir: Jan Homann, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
de réir: Alexander Neumann, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort
de réir: Jin Xu, et al.
Foilsithe / Cruthaithe: (2021-11-01)

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
de réir: Kirsten E. J. Wesenhagen, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
de réir: Claudia Cicognola, et al.
Foilsithe / Cruthaithe: (2021-02-01)

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics
de réir: Isabelle Bos, et al.
Foilsithe / Cruthaithe: (2018-07-01)

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
de réir: Bos, I, et al.
Foilsithe / Cruthaithe: (2019)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
de réir: Flora H. Duits, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies
de réir: Liu Shi, et al.
Foilsithe / Cruthaithe: (2021-07-01)

Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
de réir: Chiara Giangrande, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Peptidome analysis of cerebrospinal fluid by LC-MALDI MS.
de réir: Mikko Hölttä, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study
de réir: Jori Tomassen, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks
de réir: Yuting Zhang, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis
de réir: Bridel, C, et al.
Foilsithe / Cruthaithe: (2019)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
de réir: Elena Camporesi, et al.
Foilsithe / Cruthaithe: (2021-02-01)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
de réir: Eleonora M. Vromen, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Levels of ADAM10 are reduced in Alzheimer’s disease CSF
de réir: Aitana Sogorb-Esteve, et al.
Foilsithe / Cruthaithe: (2018-07-01)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
de réir: Johanna Nilsson, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
de réir: Nicholas J. Ashton, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
de réir: Thomas K. Karikari, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
de réir: Mara ten Kate, et al.
Foilsithe / Cruthaithe: (2017-09-01)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
de réir: Eline A. J. Willemse, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Corrigendum to “Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease” [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82]
de réir: Karl Hansson, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
de réir: Henrik Zetterberg, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer’s Disease
de réir: Tina E. Brinkley, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
de réir: Rosha Babapour Mofrad, et al.
Foilsithe / Cruthaithe: (2019-12-01)

Early diagnosis of silent coronary artery disease in diabetic subjects - are intense efforts worth while?
de réir: KEJ Airaksinen
Foilsithe / Cruthaithe: (2001-07-01)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
de réir: Nicholas J. Ashton, et al.
Foilsithe / Cruthaithe: (2019-12-01)